Medtronic, DaVita to form new kidney care company

Medtronic (NYSE:MDT) and DaVita (NYSE:DVA) today announced the intent to form a new medical device company for kidney care.

The new, independent company — dubbed “NewCo” — aims to enhance the patient treatment experience and improve overall outcomes for kidney care patients.

According to a news release, the new company will bring together Medtronic’s capabilities as a healthcare technology leader and DaVita’s expertise as a comprehensive kidney care provider. NewCo will focus on developing a wide range of novel kidney care products and solutions, including future home-based products to make different dialysis treatments more accessible.

“This is an exciting moment that will shape the future of kidney care,” Ven Manda, president of Medtronic’s renal care solutions business and NewCo’s CEO upon close, said in the release. “Our singular focus on end-to-end kidney health solutions will position this new c…

Read more
  • 0

Fresenius to provide more home dialysis machines to DaVita

A NxStage home hemodialysis machine [Image courtesy of Fresenius Medical Care] Fresenius Medical Care North America (FMCNA) has expanded its agreement with DaVita Kidney Care to provide NxStage home hemodialysis machines and related technology to DaVita’s U.S. patients.

“We are excited to expand our longstanding collaboration with DaVita to help more patients benefit from the portability, dependability, and flexibility of our NxStage home machines, which are designed to be easy to use,” Joe Turk, president of Home and Critical Care Therapies for FMCNA, said in a news release out today.

Under the agreement, DaVita patients will also access Nx2me Connected Health, a connected health platform that simplifies collection and sharing of treatment information with the dialysis clinic and care team. Nx2me Connected Health accesses treatment information directly from home hemodialysis machines.

Keith Hartman, group vice president for DaVita home modalities, sa…

Read more
  • 0

CMS delays shift to new payment model for chronic kidney disease treatments

CMS will now wait until Jan. 1, 2022 to start its Kidney Care Choices model, meant to shift the way the U.S. treats chronic kidney disease.

The new payment model was supposed to start on Jan. 1 of this year, but health providers are still grappling with the COVID-19 pandemic.

The new model could have a major effect on dialysis treatment providers including DaVita Healthcare (NYSE:DVA) and Fresenius Medical Care (NYSE:FMS; ETR:FRE). Baxter (NYSE:BAX) meanwhile announced in 2019 that it was investing in technologies to support the effort.

The new model’s roots go back to former President Donald Trump’s 2019 executive order to emphasize transplants and home hemodialysis over in-clinic treatment. End-stage renal disease is one of the few conditions in the United States where there is already a single-payer system, thanks to a law signed by President Richard Nixon in 1972.

The Kidney Care Choices (KCC) model would provide strong financial i…

Read more
  • 0